FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

			 •
ashington	. D.C. 2	0549	

gton, D.C.	20549		

ONID APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Saad Mark E					2. Issuer Name and Ticker or Trading Symbol Axsome Therapeutics, Inc. [AXSM]							(Ch	Relationship eck all appli X Directo	cable)	Person(s) to	Ssuer Owner		
(Last)	(Fi	rst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/02/2023								Officer below)	(give title	Othe belov	(specify	
C/O AXSOME THERAPEUTICS, INC. ONE WORLD TRADE CENTER, 22ND FLOOR					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) NEW Y	ORK N	Y	10007											Form Perso		than One Re	porting	
(City)	(Si	,	(Zip)	n-Deriv		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Ative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				action	2A. Deemed Execution Date,			3. Transac Code (Ir	tion	4. Securities Acquired (A Disposed Of (D) (Instr. 3,		ed (A) or	5. Amou Securiti Benefic	int of 6 es I ially (Following (6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	nt (A) or (D)		Transac (Instr. 3	tion(s)		(111501.4)				
		Т							quired, Di s, option					Owned				
Derivative Conversion Date Execution Date, Tr			4. Transact Code (In 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersi Form: Direct (E or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)					
					Code	v	(A)	(D)	Date Exercisable		kpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$74.12	06/02/2023			A		5,681		06/02/2024 ^{(:}	06	6/02/2033	Common Stock	5,681	\$0.00	5,681	D		

Explanation of Responses:

1. The option vests in full on the one-year anniversary of the date of grant, June 2, 2024.

Remarks:

/S/ Herriot Tabuteau, M.D., Attorney-in-Fact

06/06/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.